Table 1. Patient characteristics.
| Characteristics | No. (%) of patients |
|---|---|
| Total patients | 39 |
| Age (median) | |
| <70 yr | 19 |
| ≥ 70 yr | 20 (47-80) |
| Performance state (ECOG) | |
| 0 | 30 (76.9) |
| 1 | 8 (20.5) |
| 2 | 1 (2.6) |
| Comorbidity | |
| No | 17 (43.6) |
| Yes | 22 (56.4) |
| Stage | |
| T1c | 26 (66.7) |
| T2a | 4 (10.3) |
| T2b | 5 (12.8) |
| T2c | 4 (10.3) |
| Gleason score | |
| 2-6 | 29 (74.4) |
| 7 | 10 (25.6) |
| Initial PSA (median) | 7.7 ng/mL (2.7-19.5) |
| Risk group | |
| Low | 16 (41.0) |
| Intermediate | 23 (59.0) |
| GTV (median) | 49.5 mL (25.0-94.8) |
| PTV (median) | 96.8 mL (51.2-154.0) |
| Isodose line (median) | 80 (78-84) |
| Dose of radiotherapy (fraction) | 37.5 Gy (5) |
ECOG, eastern cooperative oncology group; PSA, prostate specific antigen; GTV, gross target volume; PTV, planning target volume.